high cardiovascular risk
Showing 1 - 25 of >10,000
Cardiovascular Diseases, Uric Acid Trial (Allopurinol 200 mg, Optional intervention)
Not yet recruiting
- Cardiovascular Diseases
- Uric Acid
- Allopurinol 200 mg
- Optional intervention
- (no location specified)
Jul 5, 2023
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Oncologic Disorders, Cardiovascular Diseases Trial in Vila Nova De Gaia (Cardiac Rehabilitation Program, Community exercise
Completed
- Oncologic Disorders
- Cardiovascular Diseases
- Cardiac Rehabilitation Program
- Community exercise intervention
-
Vila Nova De Gaia, Porto, PortugalCentro Hospitalar Vila Nova de Gaia Espinho, E.P.E.
Oct 1, 2022
Carotid Ultrasound to Identify Head and Neck Cancer Survivors
Not yet recruiting
- Head and Neck Cancer
- +2 more
- Carotid ultrasound
- +2 more
- (no location specified)
Aug 4, 2022
Metabolic Syndrome, Cardiovascular Risk Factor Trial in Athens (Probiotic mix, Placebo)
Withdrawn
- Metabolic Syndrome
- Cardiovascular Risk Factor
- Probiotic mix
- Placebo
-
Athens, GreeceAttikon University General Hospital
Mar 30, 2022
Qualitative Features of Atherosclerotic Plaques
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
-
Riga, LatviaPauls Stradins Clinical University Hospital
Dec 5, 2022
Cardiovascular Disease Trial in Sao Paulo (polipillV1, polipillV2, usual care)
Withdrawn
- Cardiovascular Disease
- polipillV1
- +2 more
-
Sao Paulo, BrazilInstituto de Ensino e Pesquisa - IEP - HCor
Sep 20, 2022
Myocardial Infarction, Hypertension, Stroke Trial in United States (BP REACH Intervention)
Not yet recruiting
- Myocardial Infarction
- +2 more
- BP REACH Intervention
-
Downey, California
- +3 more
Jun 30, 2023
2D Speckle-tracking Echocardiography in Chemotherapy-induced
Recruiting
- Cardiomyopathy Due to Drug
- +2 more
- Echocardiography
-
Ho Chi Minh, VietnamNguyen Hoang Hai
Aug 9, 2022
Prospective German Very High Cardiovascular Risk Patients
Recruiting
- Dyslipoproteinemias
- PCSK9 Inhibitor [EPC]
- Standard lipid lowering therapy
-
Dresden, GermanyMedizinische Klinik und Poliklinik III
Mar 18, 2022
Type2 Diabetes Trial in Herlev (Empagliflozin, Placebo Oral Tablet)
Completed
- Type2 Diabetes Mellitus
- Empagliflozin
- Placebo Oral Tablet
-
Herlev, DenmarkHerlev og Gentofte Hospital
Aug 17, 2022
Cardiovascular Events in a High-risk Firefighter Population
Terminated
- High Cardiovascular Risk
- Firefighter
- stress test
-
Saint-Étienne, FranceCentre Hospitalier Universitaire
Dec 21, 2021
Covid19, Atherosclerosis, Cardiovascular Diseases Trial in Oakland (Icosapent ethyl)
Active, not recruiting
- Covid19
- +3 more
- Icosapent ethyl
-
Oakland, CaliforniaKaiser Permanente Northern California
Jan 7, 2022
Disease Burden of Diabetic Patients Based on Tianjin Regional
Completed
- Diabetes
-
Chengdu, ChinaChengdu Big Data Association
Jul 14, 2022
Cardiovascular Diseases Trial in Leiden (Mixed meal test)
Recruiting
- Cardiovascular Diseases
- Mixed meal test
-
Leiden, NetherlandsLeiden University Medical Center
Apr 12, 2023
Cardiovascular Diseases, Acute Coronary Syndrome Trial in London (Active Arm, Control Arm)
Recruiting
- Cardiovascular Diseases
- Acute Coronary Syndrome
- Active Arm
- Control Arm
-
London, United KingdomImperial College Healthcare NHS Trust
Jan 26, 2022
Dyslipidemia in Patients at High Risk and Very High Risk of
Recruiting
- Secondary Prevention
- +2 more
- application
-
Leon, Guanajuato, MexicoUmae Cmn T1
Sep 13, 2022
Knee Osteoarthritis, Cardiovascular Diseases Trial (High intensity exercise)
Not yet recruiting
- Knee Osteoarthritis
- Cardiovascular Diseases
- High intensity exercise
- (no location specified)
Mar 8, 2023
Arterial Aging. The Paris Prospective Study III-2
Not yet recruiting
- Arterial Stiffness
- high-precision carotid echo-tracking
- (no location specified)
Oct 5, 2023
Improving Cardiovascular Health of High-Risk Families
Not yet recruiting
- Nutrition, Healthy
- +2 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Apr 20, 2023
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
Hypercholesterolemia Trial (ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium, Comparator: Placebo (unspecified))
Completed
- Hypercholesterolemia
- ezetimibe (+) simvastatin
- +2 more
- (no location specified)
Feb 7, 2022
Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease Trial (Intensive guideline algorithm implementation,
Not yet recruiting
- Type 2 Diabetes
- +2 more
- Intensive guideline algorithm implementation
- Conventional guideline algorithm implementation
- (no location specified)
Aug 6, 2022